News
-
Alnylam Announces FDA Approval of AMVUTTRA® (Vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults. AMVUTTRA is an RNAi therapeutic that…
-
Legislative Advocacy Updates June 2025
Nevada Adopts Component of Children’s Cardiac Safety Bill introduced by HCMA Legislative Advocate Jane Grossman Nevada HCMA Legislative State Champion Jane Grossman helped introduce…
-
Cytokinetics Announces Positive Topline Results from MAPLE-HCM
Trial Studies Aficamten in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from…
-
Camzyos® Receives Manufacturing and Marketing Approval for HOCM in Japan
2025/03/27 Bristol-Myers Squibb Company Translated from JapaneseRead the original press release (Japanese) Download the pdf file (Japanese) *The information contained in this press release…
-
US FDA Updates Camzyos Label for oHCM
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications for Obstructive HCM Label updates include simplified twice-yearly…
-
Press Release: Piedmont Heart Recognized as an HCM COE
Piedmont’s Hypertrophic Cardiomyopathy Program Recognized as an HCMA Center of Excellence April 18, 2025 Piedmont Heart has been recognized as a Center of Excellence…
-
HCMA Gifted $1500 Harrah’s Grant
HCMA Gifted $1500 Harrah’s “Funner Model Citizen Share the Wealth” Grant By Award Winner Terri Loviato April 10, 2025 Harrah’s Southern California Resort in…
-
Press Release: UW Medicine Recognized as an HCM COE
The Hypertrophic Cardiomyopathy Association Welcomes Our Newest Recognized Center of Excellence – UW Medicine Hypertrophic Cardiomyopathy Clinic March 21, 2025 We are proud to…
-
Camzyos Is Safe
REMS works to find, stop, heart failure The new drug Camzyos (mavacamten) has been nothing less than life changing for some patients who have…
-
Press Release: Johns Hopkins Recognized as an HCM COE
The Hypertrophic Cardiomyopathy Association Welcomes Our Newest Recognized Center of Excellence – Johns Hopkins HCM Center February 28, 2025 1.3 million Americans suffer from…
-
Press Release: Wellstar Recognized as an HCM COE
The Hypertrophic Cardiomyopathy Association Welcomes Our Newest Recognized Center of Excellence – Wellstar Center for Cardiovascular Care February 21, 2025 1.3 million Americans—suffer from…
-
Press Release: Virginia Mason Recognized as an HCM COE
Virginia Mason Franciscan Health Recognized by the HCMA for National Cardiovascular Care Excellence January 31, 2025 Virginia Mason Franciscan Health’s (VMFH) the Center for…
